4 Matching Annotations
  1. May 2021
  2. www.medrxiv.org www.medrxiv.org
    https://medrxiv.org/cgi/content/10.1101/2021.05.14.21257248
    1
    1. Marlene_Wulf 30 May 2021

      Gobeil, P., Pillet, S., Séguin, A., Boulay, I., Mahmood, A., Vinh, D. C., Charland, N., Boutet, P., Roman, F., Most, R. V. D., Perez, M. de los A. C., Ward, B. J., & Landry, N. (2021). Interim Report of a Phase 2 Randomized Trial of a Plant-Produced Virus-Like Particle Vaccine for Covid-19 in Healthy Adults Aged 18-64 and Older Adults Aged 65 and Older. MedRxiv, 2021.05.14.21257248. https://doi.org/10.1101/2021.05.14.21257248

      is:preprint lang:en COVID-19 vaccine interim report trial randomized trial plant produced virus-like particle vaccine safety tolerability immunogenicity
    Visit annotations in context

    Tags

    Annotators

    URL

    medrxiv.org/content/10.1101/2021.05.14.21257248v1
  3. Mar 2021
  4. Local file Local file
    Untitled document
    1
    1. alexandra.p 19 Mar 2021

      Smith, P. (2021). Interim recommendations for use of the AZD1222 (ChAdOx1-S (recombinant)) vaccine against COVID-19 developed by Oxford University and AstraZeneca. WHO.

      is:pdf lang:en COVID-19 vaccine Oxford AstraZeneca interim guidance WHO SAGE recommendation clinical trial efficacy interdose interval

    Tags

    Annotators

  5. Feb 2021
  6. www.who.int www.who.int
    Interim recommendations for use of the AZD1222 (ChAdOx1-S (recombinant)) vaccine against COVID-19 developed by Oxford University and AstraZeneca
    1
    1. zoe_ikeotuonye 16 Feb 2021

      Interim recommendations for use of the AZD1222 (ChAdOx1-S (recombinant)) vaccine against COVID-19 developed by Oxford University and AstraZeneca. (n.d.). Retrieved 16 February 2021, from https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1

      lang:en COVID-19 is:article advice immunization interim guidance vaccine Oxford University SAGE vaccination pandemic critical preparedness readiness response interim guidance
    Visit annotations in context

    Tags

    Annotators

    URL

    who.int/publications-detail-redirect/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1
  7. Jan 2021
  8. www.nejm.org www.nejm.org
    Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM
    1
    1. marta_radosevic 20 Jan 2021

      Sadoff, J., Le Gars, M., Shukarev, G., Heerwegh, D., Truyers, C., de Groot, A. M., Stoop, J., Tete, S., Van Damme, W., Leroux-Roels, I., Berghmans, P.-J., Kimmel, M., Van Damme, P., de Hoon, J., Smith, W., Stephenson, K. E., De Rosa, S. C., Cohen, K. W., McElrath, M. J., … Schuitemaker, H. (2021). Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMoa2034201

      is:article lang:en interim result trial clinical trial vaccine COVID-19 SARS safety Janssen NEJM
    Visit annotations in context

    Tags

    Annotators

    URL

    nejm.org/doi/full/10.1056/NEJMoa2034201